Nasal alum-adjuvanted vaccine promotes IL-33 release from alveolar epithelial cells that elicits IgA production via type 2 immune responses

• Published in: PLoS pathogens Vol. 17; no. 8; p. e1009890
• Main Authors: Sasaki, Eita, Asanuma, Hideki, Momose, Haruka, Furuhata, Keiko, Mizukami, Takuo, Hamaguchi, Isao
• Format: Journal Article
• Language: English
• Published: San Francisco, CA USA Public Library of Science 30.08.2021; Public Library of Science (PLoS)
• Subjects: Biology and Life Sciences; Genetic aspects; Health aspects; Immune response; Immunoglobulins; Interleukins; Medicine and Health Sciences; Patient outcomes; People and Places; Research and Analysis Methods; Vaccination; Japan

Aluminum hydroxide salts (alum) have been added to inactivated vaccines as safe and effective adjuvants to increase the effectiveness of vaccination. However, the exact cell types and immunological factors that initiate mucosal immune responses to alum adjuvants are unclear. In this study, the mecha...